All Medicinal Chemistry articles
-
NewsProtein modifications control drug binding and efficacy in new study
New research reveals that subtle chemical changes to proteins after synthesis play a critical role in determining drug-protein interactions.
-
NewsNovel enzyme inhibitors exploits key weakness in malaria parasite
Researchers from the Universities of Bath and Leeds have engineered a novel class of aminopeptidase P inhibitors with enhanced binding affinity and antiparasitic activity against Plasmodium falciparum.
-
NewsSafer diazo compound synthesis advances medicinal chemistry capabilities
Researchers at Tokyo University of Science have developed a safer synthetic route to β-heteroatom-substituted diazo esters, eliminating the need for toxic diazomethane. The azide-to-diazo conversion method uses mild conditions and readily available starting materials, potentially streamlining early-stage drug discovery and compound library synthesis.
-
NewsNew SEE-CITE technology maps drug-protein interactions with targeted precision
A UCLA-led research team has developed SEE-CITE, an advanced photo-crosslinking technology that enables direct comparison of drug-protein binding interactions, potentially aiding the discovery of safer, more effective therapeutics across multiple disease areas.
-
NewsHybrid molecule shows enhanced metabolic effects in obesity study
A novel hybrid molecule combining incretin therapy with targeted intracellular delivery of a PPAR agonist has demonstrated strong weight loss and glucose control compared to existing GLP-1/GIP therapies in preclinical studies.
-
NewsNew approach targets ‘undruggable’ proteins in prostate cancer
A novel drug design strategy has achieved binding strengths up to a million times greater than previous approaches against intrinsically disordered proteins, potentially leading to new treatments for prostate cancer and other diseases involving these historically intractable targets.
-
NewsNew method streamlines C–N bond formation for amine synthesis
Researchers at the University of Wisconsin–Madison have reported a new approach to forming carbon–nitrogen bonds, a critical step in the synthesis of amines widely used in pharmaceuticals, agrochemicals and polymers.
-
ArticleFrom leaderboards to lab notebooks: AI designs reach preclinical testing
For years, AI drug discovery has been judged on benchmark performance. Now, a set of studies shows what happens when those designs are made and tested in preclinical settings.
-
NewsAI platform models protein flexibility to accelerate drug design
A new artificial intelligence platform developed at the University of Virginia addresses a critical limitation in computational drug design by modelling protein flexibility during molecular interactions. The suite of tools uses diffusion models to generate drug candidates whilst accounting for induced fit dynamics, potentially improving success rates in early-stage development.
-
NewsInsilico announces ISM6200 AI-designed drug candidate for ovarian cancer and cortisol disorders
Insilico Medicine has nominated ISM6200, a preclinical drug candidate designed using generative AI to target NR3C1, a receptor involved in cortisol regulation.
-
NewsMassey Cancer Center funds drug discovery projects targeting Hsp27-CerS1 and ferroptosis pathways
The VCU Massey Comprehensive Cancer Center has awarded $50,000 each to two innovative drug discovery projects through its collaborative programme with Sanford Burnham Prebys Medical Discovery Institute.
-
NewsMolecular map reveals thromboxane receptor structure for new blood clotting drug development
International researchers have mapped the structure of the thromboxase A₂ receptor using cryo-electron microscopy, revealing some unexpected activation mechanisms.
-
ArticleAI builds dual-action cancer drug targeting PKMYT1
Research published in Nature Communications shows how generative AI can be used to design complex dual-action cancer drug candidates. Insilico Medicine has developed a PKMYT1 degrader that both eliminates the target protein and blocks its activity, demonstrating the growing role of AI in advanced drug discovery.
-
NewsMirrored molecules target disordered proteins in Alzheimer’s disease
Researchers at Kobe University have developed a novel approach to Alzheimer’s disease treatment by engineering right-handed amino acid chains that bind to amyloid-beta proteins. The method, inspired by materials science principles of chirality, demonstrated effective inhibition of toxic protein aggregation in mouse brain cell cultures, maintaining cell viability where amyloid-beta alone reduced it by 50 percent.
-
NewsLight-driven chemistry offers faster, greener drug design
Scientists at the University of Cambridge have developed a light-powered method to modify complex drug molecules without toxic chemicals, enabling faster, cleaner and more efficient drug development.
-
NewsNew AI tool could accelerate drug discovery and cut lab costs
Scientists have developed a machine learning system that can predict how complex chemical reactions will produce the correct molecular form for medicines.
-
InterviewHow self-driving labs are changing drug development
Automation and artificial intelligence are changing how scientists design, test and refine new molecules. At the University of Toronto, Stuart R Green and the Acceleration Consortium are building a self-driving lab that could change the pace of early drug discovery.
-
ArticleDisrupting the biologics market through innovations in macrocycle R&D
New macrocycle technologies are turning a once difficult drug class into a scalable engine for developing potent oral therapies.
-
NewsNew study revives long-doubted target for depression drugs
Researchers have shown that changing the molecular structure of NK1 receptor antagonists may restore antidepressant effects after decades of failed trials.
-
NewsAI-powered CKD drug ISM4808 licensed for kidney disease therapy
Insilico Medicine has partnered with TaiGen Biotechnology to exclusively license its AI-designed PHD inhibitor, ISM4808, for the treatment of CKD-related anaemia in Greater China.